Youth at Risk of Being Left Behind in Asia Pacific Tuberculosis Response, Regional Forum Spotlights
Johnson & Johnson, together with the Global Fund and Asian Venture Philanthropy Network, convene 2nd annual Asia Pacific Tuberculosis Forum to advance progress toward ending tuberculosis in the region Youth are at risk of being missed from diagnosis if not engaged and empowered in fight against ...
Johnson & Johnson Announces Positive CHMP Opinion for a Booster Shot of its COVID-19 Vaccine
NEW BRUNSWICK, N.J., Dec. 15, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a Positive Opinion for use of the Company's COVID-19 vaccine as a booster for...
Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., March 29, 2021 /PRNewswire/ -- Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Task Team (AVATT) to make available up to 220 million dos...
Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen's COVID-19 Vaccine Candidate
Agreement provides option for European Union Member States to secure up to 200 million additional doses for a total of up to 400 million doses NEW BRUNSWICK, N.J., Oct. 8, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the European Commission (EC), acting on beh...
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate
NEW BRUNSWICK, New Jersey, Sept. 23, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical ...
Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
NEW BRUNSWICK, New Jersey, Aug. 5, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses...
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies
Study published in Nature shows J&J's investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection First-in-human Phase 1/2a clinical trial now underway in United States and Belgium; Phase 3 clinical trial expected to commence in September NEW BR...
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest bySeptember 2020 Johnson & Johnson Will Establish New U.S. Vaccine Manufacturing Capab...
Johnson & Johnson Vision Introduces TECNIS Synergy™ IOL, a Continuous-Range-of-Vision Intraocular Lens (IOL) at the ESCRS 2019 Congress
- TECNIS Synergy™ IOL delivers continuous high-contrast vision for patients with cataracts from far through near, even in low-light conditions¹‚² - Clinical data being presented demonstrates TECNIS Synergy™ IOL gives broad range of continuous vision and offers patients the freedom to focus within...
Johnson & Johnson Completes Acquisition of Ci:z Holdings Co., Ltd.
Acquisition Expands J&J's Portfolio of Science-based Dermocosmetic Beauty Products NEW BRUNSWICK, New Jersey, Jan. 17, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the completion of the acquisition of Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company") for a total purchase p...
Singapore National Eye Centre, Singapore Eye Research Institute And Johnson & Johnson Vision Set Sights On Halting Global Myopia Epidemic
New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition SINGAPORE, Nov. 12, 2018 /PRNewswire/ -- The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and Johnson & Johnson Vision today announced aUS$26.35 ...
Johnson & Johnson Announces Offer to Acquire Ci:z Holdings Co., Ltd.
Acquisition is Expected to Expand J&J's Consumer Portfolio of Science-based Dermocosmetic Beauty Products NEW BRUNSWICK, New Jersey, Oct. 23, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that they have agreed with Ci:z Holdings Co., Ltd. (TYO: 4924) (the "Company"), a Japan...
Johnson & Johnson Completes Divestiture of LifeScan to Platinum Equity
NEW BRUNSWICK, New Jersey, Oct. 2, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has completed the divestiture of its LifeScan business to Platinum Equity for approximately$2.1 billion. LifeScan, Inc. is a world leader in blood glucose monitoring and maker of the On...
Johnson & Johnson Announces Acceptance of Binding Offer From Platinum Equity To Acquire LifeScan, Inc.
NEW BRUNSWICK, New Jersey, June 13, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has accepted the binding offer from Platinum Equity, previously announced onMarch 16, 2018, to acquire its LifeScan business for approximately$2.1 billion. LifeScan, Inc. is a world lead...
Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.
NEW BRUNSWICK, New Jersey, March 16, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately$2.1 billion, subject to customary adjustments. L...
Johnson & Johnson Innovation Launches Digital Beauty QuickFire Challenge to Tackle some of the Toughest Consumer Skincare Problems
SAN FRANCISCO, Nov. 13, 2017 /PRNewswire/ -- Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., today announced the launch of the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies to create the most novel, future-forward digi...
Ortho Clinical Diagnostics to Present Data on Early Detection Of Acute Kidney Injury, Total Lab Automation and Transfusion Medicine at MEDLAB Asia Pacific 2017
Sponsored educational sessions and product demonstrations at 4th MEDLAB Asia Pacific Congress for lab professionals followed by Ortho Clinical Diagnostics Asia Pacific Lab Leadership Summit 2017 SINGAPORE, April 4, 2017 /PRNewswire/ -- Ortho Clinical Diagnostics (Ortho), a global leader of in v...
Johnson & Johnson Issues Call for Innovative Ideas to Reduce HIV Infections in Sub-Saharan Africa
NEW BRUNSWICK, N.J., Feb. 17, 2016 /PRNewswire/ -- Johnson & Johnson (NYSE:
JNJ) todayissued a call
